FDA related matters including issues related to "biosimilar products", prescription drug "track and trace" and orphan drug products S. Con. Res 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014
H Con Res 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 15 through 2033
HR 933 -- Consolidated and Further Continuing Appropriations Act, 2013In all of the above specific issues included potential Medicare offsets that might be applied to prescription drugs, especially changes to ASP, physician payment and oncology matters S. Con. Res 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014
H Con Res 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 15 through 2033
HR 933 -- Consolidated and Further Continuing Appropriations Act, 2013In all of the above specific issues included potential Medicare offsets that might be applied to prescription drugs Implementation of the new health care reform law - PL 111-148, specifically with regard to those provisions impacting Medicare/Medicaid prescription drug coverage in the essential benefit package, and other matters.
PHA - Pharmacy MMM - Medicare/Medicaid BUD - Budget/Appropriations HCR - Health Issues
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
750 9th Street N.W. Suite 575, WASHINGTON, DC, 20001, US
AARTI SHAH AARTI SHAH AARTI SHAH AARTI SHAH